

September 28, 2015

To Whom It May Concern:

Company Name: Taisho Pharmaceutical Holdings Co., Ltd.
Head Office: 3-24-1, Takada, Toshima-ku, Tokyo
Representative: Akira Uehara, President and CEO
(First Section of TSE: Code 4581)
Contact: Takashi Shibata, General Manager
Corporate Communications
(Tel: +81-3-3985-1115)

Acquisition of Manufacturing and Marketing Approval in Japan for the Transdermal Anti-inflammatory Analgesic Patch Formulation LOQOA[®] Tape

Taisho Pharmaceutical Holdings Co., Ltd. has announced that its consolidated subsidiary Taisho Pharmaceutical Co., Ltd. (“Taisho Pharmaceutical”) [Head Office: Toshima-ku, Tokyo, President: Shigeru Uehara] today received manufacturing and marketing approval for the transdermal anti-inflammatory analgesic patch formulation LOQOA[®] Tape (Development Code: TT-063, hereinafter “LOQOA[®] Tape”) from the Ministry of Health, Labour and Welfare for the indication and usage of “the treatment of osteoarthritis pain and inflammation.” LOQOA[®] Tape was created by Taisho Pharmaceutical Holdings Co., Ltd.’s consolidated subsidiary TOKUHON Corporation (“TOKUHON”) [Head Office: Toshima-ku, Tokyo; President: Jun-ichi Fukudome], and was co-developed by Taisho Pharmaceutical and TOKUHON in Japan.

LOQOA[®] Tape is a non-steroidal anti-inflammatory drug (NSAID) patch formulation containing the active ingredients S-flurbiprofen, which is the active form of flurbiprofen, and mentha oil. The patch formulation is designed to provide enhanced drug delivery to the lesion area. In clinical trials, LOQOA[®] Tape was found to demonstrate good efficacy and a strong safety profile in connection with osteoarthritis.

Osteoarthritis is a chronic degenerative disease of the joints, mainly involving degeneration and abrasion of joint cartilage. Approximately 30% of osteoarthritis patients show symptoms of pain. Considering that pain is a major cause of reduced quality of life (QOL), there are high hopes for the development of powerful patch formulations that possess an anti-inflammatory analgesic action.

LOQOA[®] Tape is scheduled to be co-marketed in Japan by Taisho Pharmaceutical Holdings Co., Ltd.’s consolidated subsidiary Taisho Toyama Pharmaceutical Co., Ltd. (“Taisho Toyama Pharmaceutical”) [Head Office: Toshima-ku, Tokyo; President Kenichi Fujita] and Teijin Pharma Limited (“Teijin Pharma”) [Head Office: Chiyoda-ku, Tokyo; President: Hiroshi Uno].

Through the marketing of the transdermal anti-inflammatory analgesic patch formulation LOQOA[®] Tape, Taisho Pharmaceutical seeks to provide many more patients with a new treatment option for osteoarthritis pain and inflammation.

Outline of Approval

Product name	LOQOA [®] Tape
Generic name	S-flurbiprofen, mentha oil
Indication and usage	Treatment of osteoarthritis pain and inflammation
Dosage and administration	Apply to the lesion area once daily. Do not apply more than two patches simultaneously.
Ingredients and concentration	40 mg of S-flurbiprofen and 36.2 mg of Japanese Pharmacopoeia mentha oil per 10 cm x 14 cm patch